A division of Valeant Pharmaceuticals named Medicis Aesthetics Canada will market Dysport in the region.
Ipsen’s group corporate strategy executive vice-president Pierre Boulud said, "This presentation is in line with Ipsen’s commitment to an increased focus and investment behind Dysport and to extend its geographical footprint. After its approval in 2009 in the United States, Dysport will now be available in Canada for the treatment of glabellar lines."
Dysport (Botulinum toxin type A for injection) is indicated for the use in moderate to severe frown lines (glabellar lines) in adult patients below 65 years old.